Zonsen PepLib Biotech Inc.
Zonsen PepLib Biotech Inc. is a high-tech biopharmaceutical enterprise that is dedicated to advancing global innovation in the discovery of new peptide drugs. Founded in September 2017, PepLib is headquartered in Zhuzhou, China, with a subsidiary in New Jersey, USA.
Our core peptide discovery platform is called Peptide Information Compression Technology (PICT), which consists of a diverse peptide library named ZSenithFive®, containing information on nearly half-billion peptides. The PICT platform is ideal for the discovery of functionally active peptides directly from cell-based and biochemical high-throughput screening (HTS) assays. In addition, we have developed 4 complimentary peptide discovery platforms: the Disulfide-rich Peptide Phage Display (DRP-PD) platform, the Animal Toxin Peptide Library Platform, the Nano-Cyclic Peptide Library Platform, and the Virtual Peptide Library Platform.
PepLib successfully raised 100 million yuan (USD 16 million) in Series Pre-A financing in 2019 and secured Series A financing of 220 million yuan (USD 35 million) in 2021. PepLib has been working towards Series Pre-IPO financing since August 2023. PepLib has more than 190 employees, and more than 80% of the workforce is made up of R&D personnel.
At PepLib, our main therapeutic area focus is oncology and cardiometabolic diseases. where oncology programs are driven by the development of peptide drug conjugates (PDCs) and peptide radionuclide conjugates (PRCs).
R&D Input
Accumulated R&D input of approximately 380 million yuan, with 600 million yuan expected to be invested in the next 3 years.
New Drug Milestone Service + Self-developed Pipelines.
.
Company Appearance
FLIPR tetra
Biotek Cytation10
Biotek Cytation5
Biotek Synergy neo2